- Trial Phase
- Preclinical (nonclinical / IND-enabling; no human trial registered)
- Time to Market
- Unknown and likely years away: no human data exists yet; first clinical evaluation is planned as early as Q4 2026 with an initial readout guided to H1 2027, and no regulatory/approval timeline has been set.
- Why 2/10
- No hard, dated binary exists for LT-100 in the next ~12 months: the drug is still at the nonclinical/development-strategy stage, and the company's targets — clinical evaluation "as early as Q4 2026" and an "initial readout" in H1 2027 — are soft, company-guided timelines with no registered trial, PDUFA, or readout date, so impactScore stays low.
Treat LT-100 as an early-stage pipeline story inside a distressed micro-cap: the stock's near-term moves are being driven by the July 14, 2026 reverse merger, massive shareholder dilution, and Nasdaq compliance risk, not by LT-100 data (there is none in humans yet). Watch for (1) actual clinical-trial initiation around Q4 2026 and any H1 2027 readout, (2) the required shareholder meeting approving share issuances above the 19.99% cap, and (3) whether the company regains Nasdaq minimum bid-price/equity compliance — delisting risk alone can swamp any LT-100 upside.
Price Chart
Executive Summary
LT-100 is the lead development program of Lōkahi Therapeutics, the San Diego biopharma that took control of Glucotrack, Inc. (Nasdaq: GCTK) via a reverse merger closed July 14, 2026 — Lōkahi holders received ~90% of post-merger equity, cutting legacy Glucotrack shareholders to roughly 10%. LT-100 is still pre-clinical: an FDA Type C meeting (May 2026) and a minipig study support a planned first clinical evaluation as early as Q4 2026 with an initial readout guided to H1 2027, but there is no human efficacy data, no registered trial, and no dated binary. The stock context is heavily bearish — ~30.95% of estimated shares outstanding held short (settlement 7/15/26), Reg SHO threshold-list entry since 7/20/26, a ~56% short-volume day on 7/30/26, a Nasdaq volatility pause, and pending delisting risk.
How It Works
LT-100 is an injectable biologic (a protein-based medicine) that Lōkahi describes as a "non-opioid" therapy — i.e., aimed at delivering therapeutic benefit without opioid drugs. It is given by injection; the old regimen required up to 15 small skin-level (intradermal) injections per treatment visit, and the new strategy is a single deeper (subcutaneous) injection. The specific disease indication and mechanism were not disclosed in any source retrieved this session, so they remain unconfirmed.
Trial Status
Per Glucotrack's July 30, 2026 8-K, Lōkahi held an FDA Type C meeting in May 2026 to discuss LT-100 clinical strategy and completed a nonclinical minipig study comparing subcutaneous vs. intradermal dosing. The program is pivoting from a historically burdensome up-to-15-intradermal-injections-per-visit regimen to a single subcutaneous injection. Clinical evaluation is targeted to begin as early as Q4 2026 with an initial readout possibly in H1 2027. No ClinicalTrials.gov records, FDA actions, or analyst coverage were found in local SecBot data.
The Two-Sided Case
Upcoming Catalysts
- Initiation of LT-100 clinical evaluation (company guidance: as early as Q4 2026) and any initial readout (guided to H1 2027) — soft targets, not confirmed dates
- Shareholder meeting required within 60 days of merger close to approve share issuances above the 19.99% exchange cap — outcome affects dilution
- Nasdaq continued-listing determination (minimum bid price and stockholders' equity) following the June 18, 2026 Hearings Panel appearance
- Semi-monthly FINRA short-interest updates and Reg SHO threshold-list status (entered 7/20/26, still current)
- Future capital raises under the White Lion ELOC / convertible note, which would add further dilution
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Glucotrack, Inc. 8-K GCTK ·Originating report